Recent Progress in the Treatment of Proliferative Lupus Nephritis

Abstract The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of medicine Vol. 125; no. 7; pp. 642 - 648
Main Author Chan, Tak Mao, MD, FRCP
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.07.2012
Elsevier
Elsevier Sequoia S.A
Subjects
Azathioprine
Biological and medical sciences
Cyclophosphamide
Cyclophosphamide - therapeutic use
General aspects
Humans
Immunosuppressive Agents - therapeutic use
Internal Medicine
Kidneys
Lupus
Lupus nephritis
Lupus Nephritis - drug therapy
Medical sciences
Medical treatment
Mycophenolate mofetil
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Nephrology. Urinary tract diseases
Quality of life
Risk factors
Urinary system involvement in other diseases. Miscellaneous
Cyclophosphamide
Lupus nephritis
Mycophenolate mofetil
Azathioprine
Kidney disease
Cell proliferation
Medicine
Immunopathology
Connective tissue disease
Skin disease
Urinary system disease
Treatment
Systemic disease
Autoimmune disease
Online AccessGet full text

Cover

Abstract Abstract The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the dosing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk.
AbstractList The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the closing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk. [PUBLICATION ABSTRACT]
The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the dosing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk.
Abstract The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the dosing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk.
Author Chan, Tak Mao, MD, FRCP
Author_xml – sequence: 1
  fullname: Chan, Tak Mao, MD, FRCP
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26163173$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22608789$$D View this record in MEDLINE/PubMed
BookMark eNqFkl1rFTEQhoO02NPqPxBZEMGbXSfZfGxuhFL8KBxUtIJ3Ic1ObNb9OE12C_33ZjmnFHrj1RDmed_MvMwpORqnEQl5RaGiQOX7rrJDN2BbMaCsAloB48_IhgohSkUlOyIbAGClrnl9Qk5T6vITtJDPyQljEhrV6A05_4EOx7n4Hqc_EVMqwljMN1hcRbTzsHYmvzb74DHaOdxhsV12Syq-4u4mhjmkF-TY2z7hy0M9I78-fby6-FJuv32-vDjflo4rMZcWvOBCeaqUow3YRnBF4VqBl23LETUARyE1515KWVunsGmEZ45T3XjX1mfk3d53F6fbBdNshpAc9r0dcVqSocAYEzqXjL55gnbTEsc83UppzZhWTab4nnJxSimiN7sYBhvvM2TWiE1n9hGbNWID1OSIs-z1wXy5XnsPoodMM_D2ANjkbO-jHV1Ij5yksqaqztyHPYc5tbuA0SQXcHTYhohuNu0U_jfJUwPXhzHkP__iPabHnU3KGvNzPYf1GiiD7Am_638a6q_I
CODEN AJMEAZ
CitedBy_id crossref_primary_10_1007_s10157_015_1179_y
crossref_primary_10_1016_j_jtbi_2019_03_017
crossref_primary_10_3109_08916934_2015_1054027
crossref_primary_10_1007_s00467_012_2327_1
crossref_primary_10_1111_nep_13469
Cites_doi 10.1056/NEJM200010193431604
10.1038/sj.ki.5000243
10.1056/NEJMoa1014460
10.1002/art.30293
10.1681/ASN.2008101028
10.1177/0961203310395802
10.1681/ASN.2004080686
10.1056/NEJMoa043731
10.7326/0003-4819-135-4-200108210-00009
10.1016/S0162-3109(00)00188-0
10.1093/rheumatology/kep346
10.1093/ndt/gfm775
10.1002/art.22449
10.1159/000188739
10.1016/S0140-6736(10)61354-2
10.1097/00007890-199711150-00008
10.1056/NEJM198603063141004
10.1177/0961203311418269
10.1136/ard.2008.102533
10.1111/j.1440-1797.2005.00444.x
10.1038/sj.ki.5001630
10.1136/ard.2010.131995
10.1191/0961203305lu2081oa
10.1681/ASN.2006090992
10.1038/ki.1996.528
10.1038/ki.2010.170
10.1002/art.10461
10.3899/jrheum.080517
10.1093/ndt/gfp336
10.1056/NEJM197811232992102
10.1111/j.1440-1797.2007.00862.x
10.1002/art.27233
10.1097/01.ASN.0000108969.21691.5D
10.1002/art.10142
10.1093/ndt/gfg345
10.1056/NEJMoa031855
10.1191/0961203306lu2307xx
10.1038/ki.2009.66
ContentType Journal Article
Copyright Elsevier Inc.
2012 Elsevier Inc.
2015 INIST-CNRS
Copyright © 2012 Elsevier Inc. All rights reserved.
Copyright Elsevier Sequoia S.A. Jul 2012
Copyright_xml – notice: Elsevier Inc.
– notice: 2012 Elsevier Inc.
– notice: 2015 INIST-CNRS
– notice: Copyright © 2012 Elsevier Inc. All rights reserved.
– notice: Copyright Elsevier Sequoia S.A. Jul 2012
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
7TK
7TO
7TS
7U9
H94
K9.
7X8
DOI 10.1016/j.amjmed.2012.01.024
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Physical Education Index
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Neurosciences Abstracts
Physical Education Index
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1555-7162
EndPage 648
ExternalDocumentID 2722775781
10_1016_j_amjmed_2012_01_024
22608789
26163173
S000293431200160X
1_s2_0_S000293431200160X
Genre Journal Article
Review
GroupedDBID -
08R
0R
1-
123
1B1
1P
1RT
1~5
23M
3O-
4
4.4
457
4CK
4G.
53G
55
5RE
5VS
68V
6J9
7-5
AACTN
AAEDT
AAIAV
AALRI
AAQFI
AAQQT
AAQXK
AAWTL
AAXUO
AAYOK
ABFLS
ABLJU
ABMAC
ABOCM
ABPPZ
ABPTK
ABWYI
ACGFO
ACIUM
ACKOT
ACPRK
ADBBV
ADPAM
AENEX
AEVXI
AFFNX
AFHKK
AFRHN
AFTJW
AGHFR
AGZHU
AHHHB
AHMBA
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
ALXNB
AMRAJ
ASPBG
AVWKF
AZFZN
BELOY
BKOMP
C5W
CS3
EBS
EFJIC
EJD
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FO
G-2
G-Q
GBLVA
GJ
HEA
HMK
HMO
HVGLF
HZ
IH2
IHE
IPNFZ
J1W
J5H
K
K-O
KOM
L7B
LZ2
M29
M41
MO0
MVM
N4W
N9A
NCXOZ
NQ-
O9-
OD.
OHT
OO
P2P
PC.
PQEST
PQQKQ
R2-
RIG
ROL
RPZ
SAE
SEL
SES
SSZ
TWZ
UBY
UHB
UHU
UNMZH
UV1
WH7
WOW
WUQ
X
X7M
XH2
XPP
YFH
YOC
YQJ
YYQ
Z5R
ZA5
ZGI
ZUP
ZXP
---
--K
-~X
.-4
.1-
.55
.FO
.GJ
0R~
1CY
1P~
AAEDW
ADMUD
AHPSJ
HZ~
OO~
AAUGY
IQODW
0SF
ADVLN
AFCTW
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
7TK
7TO
7TS
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c475t-a0f5457f177c180a854710b70f6dd4ee9004e56944f6663ac7e885f2c4198fcd3
ISSN 0002-9343
IngestDate Sat Aug 17 01:09:49 EDT 2024
Fri Sep 13 08:10:42 EDT 2024
Thu Sep 26 17:42:30 EDT 2024
Sat Sep 28 07:51:49 EDT 2024
Sun Oct 22 16:04:48 EDT 2023
Fri Feb 23 02:19:30 EST 2024
Thu Aug 18 17:13:10 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Cyclophosphamide
Lupus nephritis
Mycophenolate mofetil
Azathioprine
Kidney disease
Cell proliferation
Medicine
Immunopathology
Connective tissue disease
Skin disease
Urinary system disease
Treatment
Systemic disease
Autoimmune disease
Language English
License CC BY 4.0
Copyright © 2012 Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c475t-a0f5457f177c180a854710b70f6dd4ee9004e56944f6663ac7e885f2c4198fcd3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
PMID 22608789
PQID 1029922978
PQPubID 950
PageCount 7
ParticipantIDs proquest_miscellaneous_1022259102
proquest_journals_1029922978
crossref_primary_10_1016_j_amjmed_2012_01_024
pubmed_primary_22608789
pascalfrancis_primary_26163173
elsevier_sciencedirect_doi_10_1016_j_amjmed_2012_01_024
elsevier_clinicalkeyesjournals_1_s2_0_S000293431200160X
PublicationCentury 2000
PublicationDate 2012-07-01
PublicationDateYYYYMMDD 2012-07-01
PublicationDate_xml – month: 07
  year: 2012
  text: 2012-07-01
  day: 01
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
– name: New York
PublicationTitle The American journal of medicine
PublicationTitleAlternate Am J Med
PublicationYear 2012
Publisher Elsevier Inc
Elsevier
Elsevier Sequoia S.A
Publisher_xml – name: Elsevier Inc
– name: Elsevier
– name: Elsevier Sequoia S.A
References Chan, Tse, Li, Tang, Mok (bib2) 2005; 16
Grootscholten, Bajema, Florquin (bib16) 2007; 56
Houssiau, Vasconcelos, D'Cruz (bib11) 2010; 69
Navarra, Guzman, Gallacher (bib39) 2011; 377
Illei, Austin, Crane (bib9) 2001; 135
Allison, Eugui (bib17) 2000; 47
Merrill, Neuwelt, Wallace (bib36) 2010; 62
Lertdumrongluk, Somparn, Kittanamongkolchai, Traitanon, Vadcharavivad, Avihingsanon (bib34) 2010; 78
Merrill, Buyon, Furie (bib37) 2011; 20
Ginzler, Dooley, Aranow (bib19) 2005; 353
Contreras, Pardo, Leclercq (bib31) 2004; 350
Chan, Li, Tang (bib1) 2000; 343
Grootscholten, Ligtenberg, Hagen (bib15) 2006; 70
Dooley, Jayne, Ginzler (bib5) 2011; 365
Zeher, Doria, Lan (bib22) 2011; 20
Barr, Seliger, Appel (bib25) 2003; 18
Isenberg, Appel, Contreras (bib4) 2010; 49
Contreras, Lenz, Pardo (bib26) 2006; 69
Schwartz, Korbet, Lewis (bib14) 2008; 23
Houssiau, D'Cruz, Sangle (bib32) 2010; 69
Mak, Lo, Lo (bib21) 2008; 13
Costenbader, Desai, Alarcon (bib27) 2011; 63
Chan, Tse, Tang, Lai, Li (bib13) 2005; 14
Suthanthiran, Gerber, Schwartz (bib28) 2009; 76
Korbet, Schwartz, Evans, Lewis (bib24) 2007; 18
Moroni, Quaglini, Maccario, Banfi, Ponticelli (bib29) 1996; 50
Tse, Tang, Lio, Lam, Chan (bib33) 2006; 15
Ong, Hooi, Lim (bib20) 2005; 10
Furie, Looney, Rovin (bib38) 2010; 69
Houssiau, Vasconcelos, D'Cruz (bib10) 2002; 46
Austin, Klippel, Balow (bib8) 1986; 314
Tse, Tang, Lam, Yap, Chan (bib35) 2009; 36
Chan, Cheng, Li, Wong, Chan, Wong (bib12) 1995; 71
Weening, D'Agati, Schwartz (bib6) 2004; 15
Pepper, Griffith, Kirwan (bib23) 2009; 24
Neylan (bib18) 1997; 64
Donadio, Holley, Ferguson, LLstrup (bib7) 1978; 299
Illei, Takada, Parkin (bib30) 2002; 46
Appel, Contreras, Dooley (bib3) 2009; 20
Isenberg (10.1016/j.amjmed.2012.01.024_bib4) 2010; 49
Appel (10.1016/j.amjmed.2012.01.024_bib3) 2009; 20
Costenbader (10.1016/j.amjmed.2012.01.024_bib27) 2011; 63
Lertdumrongluk (10.1016/j.amjmed.2012.01.024_bib34) 2010; 78
Neylan (10.1016/j.amjmed.2012.01.024_bib18) 1997; 64
Chan (10.1016/j.amjmed.2012.01.024_bib1) 2000; 343
Houssiau (10.1016/j.amjmed.2012.01.024_bib11) 2010; 69
Chan (10.1016/j.amjmed.2012.01.024_bib2) 2005; 16
Mak (10.1016/j.amjmed.2012.01.024_bib21) 2008; 13
Houssiau (10.1016/j.amjmed.2012.01.024_bib32) 2010; 69
Chan (10.1016/j.amjmed.2012.01.024_bib12) 1995; 71
Donadio (10.1016/j.amjmed.2012.01.024_bib7) 1978; 299
Illei (10.1016/j.amjmed.2012.01.024_bib30) 2002; 46
Navarra (10.1016/j.amjmed.2012.01.024_bib39) 2011; 377
Grootscholten (10.1016/j.amjmed.2012.01.024_bib15) 2006; 70
Tse (10.1016/j.amjmed.2012.01.024_bib35) 2009; 36
Grootscholten (10.1016/j.amjmed.2012.01.024_bib16) 2007; 56
Allison (10.1016/j.amjmed.2012.01.024_bib17) 2000; 47
Merrill (10.1016/j.amjmed.2012.01.024_bib37) 2011; 20
Furie (10.1016/j.amjmed.2012.01.024_bib38) 2010; 69
Suthanthiran (10.1016/j.amjmed.2012.01.024_bib28) 2009; 76
Illei (10.1016/j.amjmed.2012.01.024_bib9) 2001; 135
Tse (10.1016/j.amjmed.2012.01.024_bib33) 2006; 15
Chan (10.1016/j.amjmed.2012.01.024_bib13) 2005; 14
Merrill (10.1016/j.amjmed.2012.01.024_bib36) 2010; 62
Dooley (10.1016/j.amjmed.2012.01.024_bib5) 2011; 365
Ginzler (10.1016/j.amjmed.2012.01.024_bib19) 2005; 353
Barr (10.1016/j.amjmed.2012.01.024_bib25) 2003; 18
Moroni (10.1016/j.amjmed.2012.01.024_bib29) 1996; 50
Contreras (10.1016/j.amjmed.2012.01.024_bib26) 2006; 69
Houssiau (10.1016/j.amjmed.2012.01.024_bib10) 2002; 46
Zeher (10.1016/j.amjmed.2012.01.024_bib22) 2011; 20
Korbet (10.1016/j.amjmed.2012.01.024_bib24) 2007; 18
Ong (10.1016/j.amjmed.2012.01.024_bib20) 2005; 10
Schwartz (10.1016/j.amjmed.2012.01.024_bib14) 2008; 23
Pepper (10.1016/j.amjmed.2012.01.024_bib23) 2009; 24
Austin (10.1016/j.amjmed.2012.01.024_bib8) 1986; 314
Contreras (10.1016/j.amjmed.2012.01.024_bib31) 2004; 350
Weening (10.1016/j.amjmed.2012.01.024_bib6) 2004; 15
References_xml – volume: 49
  start-page: 128
  year: 2010
  end-page: 140
  ident: bib4
  article-title: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
  publication-title: Rheumatology
  contributor:
    fullname: Contreras
– volume: 10
  start-page: 504
  year: 2005
  end-page: 510
  ident: bib20
  article-title: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis
  publication-title: Nephrology
  contributor:
    fullname: Lim
– volume: 314
  start-page: 614
  year: 1986
  end-page: 619
  ident: bib8
  article-title: Therapy of lupus nephritis
  publication-title: N Engl J Med
  contributor:
    fullname: Balow
– volume: 71
  start-page: 321
  year: 1995
  end-page: 327
  ident: bib12
  article-title: Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone
  publication-title: Nephron
  contributor:
    fullname: Wong
– volume: 70
  start-page: 732
  year: 2006
  end-page: 742
  ident: bib15
  article-title: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis
  publication-title: Kidney Int
  contributor:
    fullname: Hagen
– volume: 62
  start-page: 222
  year: 2010
  end-page: 233
  ident: bib36
  article-title: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus
  publication-title: Arthritis Rheum
  contributor:
    fullname: Wallace
– volume: 343
  start-page: 1156
  year: 2000
  end-page: 1162
  ident: bib1
  article-title: Efficacy of mycophenolate mofetil in diffuse proliferative lupus nephritis
  publication-title: N Engl J Med
  contributor:
    fullname: Tang
– volume: 135
  start-page: 248
  year: 2001
  end-page: 257
  ident: bib9
  article-title: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritisi
  publication-title: Ann Intern Med
  contributor:
    fullname: Crane
– volume: 20
  start-page: 1103
  year: 2009
  end-page: 1112
  ident: bib3
  article-title: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
  publication-title: J Am Soc Nephrol
  contributor:
    fullname: Dooley
– volume: 46
  start-page: 2121
  year: 2002
  end-page: 2131
  ident: bib10
  article-title: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
  publication-title: Arthritis Rheum
  contributor:
    fullname: D'Cruz
– volume: 23
  start-page: 1298
  year: 2008
  end-page: 1306
  ident: bib14
  article-title: The prognosis and pathogenesis of severe lupus nephritis
  publication-title: Nephrol Dial Transplant
  contributor:
    fullname: Lewis
– volume: 350
  start-page: 971
  year: 2004
  end-page: 980
  ident: bib31
  article-title: Sequential therapies for proliferative lupus nephritis
  publication-title: N Engl J Med
  contributor:
    fullname: Leclercq
– volume: 13
  start-page: 331
  year: 2008
  end-page: 336
  ident: bib21
  article-title: Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis
  publication-title: Nephrology
  contributor:
    fullname: Lo
– volume: 69
  start-page: 2083
  year: 2010
  end-page: 2089
  ident: bib32
  article-title: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Sangle
– volume: 63
  start-page: 1681
  year: 2011
  end-page: 1688
  ident: bib27
  article-title: Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the U.S., 1995–2006
  publication-title: Arthritis Rheum
  contributor:
    fullname: Alarcon
– volume: 365
  start-page: 1886
  year: 2011
  end-page: 1895
  ident: bib5
  article-title: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
  publication-title: N Engl J Med
  contributor:
    fullname: Ginzler
– volume: 16
  start-page: 1076
  year: 2005
  end-page: 1084
  ident: bib2
  article-title: Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis
  publication-title: J Am Soc Nephrol
  contributor:
    fullname: Mok
– volume: 69
  start-page: 61
  year: 2010
  end-page: 64
  ident: bib11
  article-title: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
  publication-title: Ann Rheum Dis
  contributor:
    fullname: D'Cruz
– volume: 78
  start-page: 389
  year: 2010
  end-page: 395
  ident: bib34
  article-title: Pharmacokinetics of mycophenolic acid in severe lupus nephritis
  publication-title: Kidney Int
  contributor:
    fullname: Avihingsanon
– volume: 299
  start-page: 1151
  year: 1978
  end-page: 1155
  ident: bib7
  article-title: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
  publication-title: N Engl J Med
  contributor:
    fullname: LLstrup
– volume: 377
  start-page: 721
  year: 2011
  end-page: 731
  ident: bib39
  article-title: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
  contributor:
    fullname: Gallacher
– volume: 56
  start-page: 924
  year: 2007
  end-page: 937
  ident: bib16
  article-title: Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Florquin
– volume: 64
  start-page: 1277
  year: 1997
  end-page: 1282
  ident: bib18
  article-title: Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
  publication-title: Transplantation
  contributor:
    fullname: Neylan
– volume: 50
  start-page: 2047
  year: 1996
  end-page: 2053
  ident: bib29
  article-title: Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis
  publication-title: Kidney Int
  contributor:
    fullname: Ponticelli
– volume: 36
  start-page: 76
  year: 2009
  end-page: 81
  ident: bib35
  article-title: Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis
  publication-title: J Rheumatol
  contributor:
    fullname: Chan
– volume: 20
  start-page: 1484
  year: 2011
  end-page: 1493
  ident: bib22
  article-title: Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis
  publication-title: Lupus
  contributor:
    fullname: Lan
– volume: 18
  start-page: 2039
  year: 2003
  end-page: 2046
  ident: bib25
  article-title: Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
  publication-title: Nephrol Dial Transplant
  contributor:
    fullname: Appel
– volume: 20
  start-page: 709
  year: 2011
  end-page: 716
  ident: bib37
  article-title: Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
  publication-title: Lupus
  contributor:
    fullname: Furie
– volume: 15
  start-page: 371
  year: 2006
  end-page: 379
  ident: bib33
  article-title: Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis
  publication-title: Lupus
  contributor:
    fullname: Chan
– volume: 15
  start-page: 241
  year: 2004
  end-page: 250
  ident: bib6
  article-title: ISN-RPS Working Group on the Classification of Lupus Nephritis
  publication-title: J Am Soc Nephrol
  contributor:
    fullname: Schwartz
– volume: 24
  start-page: 3717
  year: 2009
  end-page: 3723
  ident: bib23
  article-title: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
  publication-title: Nephrol Dial Transplant
  contributor:
    fullname: Kirwan
– volume: 76
  start-page: 72
  year: 2009
  end-page: 80
  ident: bib28
  article-title: Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans
  publication-title: Kidney Int
  contributor:
    fullname: Schwartz
– volume: 46
  start-page: 995
  year: 2002
  end-page: 1002
  ident: bib30
  article-title: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy
  publication-title: Arthritis Rheum
  contributor:
    fullname: Parkin
– volume: 47
  start-page: 85
  year: 2000
  end-page: 118
  ident: bib17
  article-title: Mycophenolic acid and its mechanisms of action
  publication-title: Immunopharmacology
  contributor:
    fullname: Eugui
– volume: 69
  start-page: 549a
  year: 2010
  ident: bib38
  article-title: Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Rovin
– volume: 18
  start-page: 244
  year: 2007
  end-page: 254
  ident: bib24
  article-title: Severe lupus nephritis: racial differences in presentation and outcome
  publication-title: J Am Soc Nephrol
  contributor:
    fullname: Lewis
– volume: 69
  start-page: 1846
  year: 2006
  end-page: 1851
  ident: bib26
  article-title: Outcomes in African Americans and Hispanics with lupus nephritis
  publication-title: Kidney Int
  contributor:
    fullname: Pardo
– volume: 14
  start-page: 265
  year: 2005
  end-page: 272
  ident: bib13
  article-title: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine
  publication-title: Lupus
  contributor:
    fullname: Li
– volume: 353
  start-page: 2219
  year: 2005
  end-page: 2228
  ident: bib19
  article-title: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
  publication-title: N Engl J Med
  contributor:
    fullname: Aranow
– volume: 343
  start-page: 1156
  year: 2000
  ident: 10.1016/j.amjmed.2012.01.024_bib1
  article-title: Efficacy of mycophenolate mofetil in diffuse proliferative lupus nephritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200010193431604
  contributor:
    fullname: Chan
– volume: 69
  start-page: 1846
  year: 2006
  ident: 10.1016/j.amjmed.2012.01.024_bib26
  article-title: Outcomes in African Americans and Hispanics with lupus nephritis
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5000243
  contributor:
    fullname: Contreras
– volume: 365
  start-page: 1886
  year: 2011
  ident: 10.1016/j.amjmed.2012.01.024_bib5
  article-title: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1014460
  contributor:
    fullname: Dooley
– volume: 63
  start-page: 1681
  year: 2011
  ident: 10.1016/j.amjmed.2012.01.024_bib27
  article-title: Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the U.S., 1995–2006
  publication-title: Arthritis Rheum
  doi: 10.1002/art.30293
  contributor:
    fullname: Costenbader
– volume: 20
  start-page: 1103
  year: 2009
  ident: 10.1016/j.amjmed.2012.01.024_bib3
  article-title: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2008101028
  contributor:
    fullname: Appel
– volume: 20
  start-page: 709
  year: 2011
  ident: 10.1016/j.amjmed.2012.01.024_bib37
  article-title: Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
  publication-title: Lupus
  doi: 10.1177/0961203310395802
  contributor:
    fullname: Merrill
– volume: 16
  start-page: 1076
  year: 2005
  ident: 10.1016/j.amjmed.2012.01.024_bib2
  article-title: Long-term study of mycophenolate mofetil as both induction and maintenance treatment for diffuse proliferative lupus nephritis
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2004080686
  contributor:
    fullname: Chan
– volume: 353
  start-page: 2219
  year: 2005
  ident: 10.1016/j.amjmed.2012.01.024_bib19
  article-title: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa043731
  contributor:
    fullname: Ginzler
– volume: 135
  start-page: 248
  year: 2001
  ident: 10.1016/j.amjmed.2012.01.024_bib9
  article-title: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritisi
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-135-4-200108210-00009
  contributor:
    fullname: Illei
– volume: 47
  start-page: 85
  year: 2000
  ident: 10.1016/j.amjmed.2012.01.024_bib17
  article-title: Mycophenolic acid and its mechanisms of action
  publication-title: Immunopharmacology
  doi: 10.1016/S0162-3109(00)00188-0
  contributor:
    fullname: Allison
– volume: 49
  start-page: 128
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib4
  article-title: Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kep346
  contributor:
    fullname: Isenberg
– volume: 23
  start-page: 1298
  year: 2008
  ident: 10.1016/j.amjmed.2012.01.024_bib14
  article-title: The prognosis and pathogenesis of severe lupus nephritis
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfm775
  contributor:
    fullname: Schwartz
– volume: 56
  start-page: 924
  year: 2007
  ident: 10.1016/j.amjmed.2012.01.024_bib16
  article-title: Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22449
  contributor:
    fullname: Grootscholten
– volume: 71
  start-page: 321
  year: 1995
  ident: 10.1016/j.amjmed.2012.01.024_bib12
  article-title: Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone
  publication-title: Nephron
  doi: 10.1159/000188739
  contributor:
    fullname: Chan
– volume: 377
  start-page: 721
  year: 2011
  ident: 10.1016/j.amjmed.2012.01.024_bib39
  article-title: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61354-2
  contributor:
    fullname: Navarra
– volume: 64
  start-page: 1277
  year: 1997
  ident: 10.1016/j.amjmed.2012.01.024_bib18
  article-title: Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
  publication-title: Transplantation
  doi: 10.1097/00007890-199711150-00008
  contributor:
    fullname: Neylan
– volume: 69
  start-page: 549a
  issue: Suppl 3
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib38
  article-title: Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Furie
– volume: 314
  start-page: 614
  year: 1986
  ident: 10.1016/j.amjmed.2012.01.024_bib8
  article-title: Therapy of lupus nephritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198603063141004
  contributor:
    fullname: Austin
– volume: 20
  start-page: 1484
  issue: 14
  year: 2011
  ident: 10.1016/j.amjmed.2012.01.024_bib22
  article-title: Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis
  publication-title: Lupus
  doi: 10.1177/0961203311418269
  contributor:
    fullname: Zeher
– volume: 69
  start-page: 61
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib11
  article-title: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.102533
  contributor:
    fullname: Houssiau
– volume: 10
  start-page: 504
  year: 2005
  ident: 10.1016/j.amjmed.2012.01.024_bib20
  article-title: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis
  publication-title: Nephrology
  doi: 10.1111/j.1440-1797.2005.00444.x
  contributor:
    fullname: Ong
– volume: 70
  start-page: 732
  year: 2006
  ident: 10.1016/j.amjmed.2012.01.024_bib15
  article-title: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5001630
  contributor:
    fullname: Grootscholten
– volume: 69
  start-page: 2083
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib32
  article-title: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.131995
  contributor:
    fullname: Houssiau
– volume: 14
  start-page: 265
  year: 2005
  ident: 10.1016/j.amjmed.2012.01.024_bib13
  article-title: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine
  publication-title: Lupus
  doi: 10.1191/0961203305lu2081oa
  contributor:
    fullname: Chan
– volume: 18
  start-page: 244
  year: 2007
  ident: 10.1016/j.amjmed.2012.01.024_bib24
  article-title: Severe lupus nephritis: racial differences in presentation and outcome
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2006090992
  contributor:
    fullname: Korbet
– volume: 50
  start-page: 2047
  year: 1996
  ident: 10.1016/j.amjmed.2012.01.024_bib29
  article-title: Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis
  publication-title: Kidney Int
  doi: 10.1038/ki.1996.528
  contributor:
    fullname: Moroni
– volume: 78
  start-page: 389
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib34
  article-title: Pharmacokinetics of mycophenolic acid in severe lupus nephritis
  publication-title: Kidney Int
  doi: 10.1038/ki.2010.170
  contributor:
    fullname: Lertdumrongluk
– volume: 46
  start-page: 2121
  year: 2002
  ident: 10.1016/j.amjmed.2012.01.024_bib10
  article-title: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
  publication-title: Arthritis Rheum
  doi: 10.1002/art.10461
  contributor:
    fullname: Houssiau
– volume: 36
  start-page: 76
  year: 2009
  ident: 10.1016/j.amjmed.2012.01.024_bib35
  article-title: Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.080517
  contributor:
    fullname: Tse
– volume: 24
  start-page: 3717
  year: 2009
  ident: 10.1016/j.amjmed.2012.01.024_bib23
  article-title: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfp336
  contributor:
    fullname: Pepper
– volume: 299
  start-page: 1151
  year: 1978
  ident: 10.1016/j.amjmed.2012.01.024_bib7
  article-title: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197811232992102
  contributor:
    fullname: Donadio
– volume: 13
  start-page: 331
  year: 2008
  ident: 10.1016/j.amjmed.2012.01.024_bib21
  article-title: Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis
  publication-title: Nephrology
  doi: 10.1111/j.1440-1797.2007.00862.x
  contributor:
    fullname: Mak
– volume: 62
  start-page: 222
  year: 2010
  ident: 10.1016/j.amjmed.2012.01.024_bib36
  article-title: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27233
  contributor:
    fullname: Merrill
– volume: 15
  start-page: 241
  year: 2004
  ident: 10.1016/j.amjmed.2012.01.024_bib6
  article-title: ISN-RPS Working Group on the Classification of Lupus Nephritis
  publication-title: J Am Soc Nephrol
  doi: 10.1097/01.ASN.0000108969.21691.5D
  contributor:
    fullname: Weening
– volume: 46
  start-page: 995
  year: 2002
  ident: 10.1016/j.amjmed.2012.01.024_bib30
  article-title: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy
  publication-title: Arthritis Rheum
  doi: 10.1002/art.10142
  contributor:
    fullname: Illei
– volume: 18
  start-page: 2039
  year: 2003
  ident: 10.1016/j.amjmed.2012.01.024_bib25
  article-title: Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfg345
  contributor:
    fullname: Barr
– volume: 350
  start-page: 971
  year: 2004
  ident: 10.1016/j.amjmed.2012.01.024_bib31
  article-title: Sequential therapies for proliferative lupus nephritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa031855
  contributor:
    fullname: Contreras
– volume: 15
  start-page: 371
  year: 2006
  ident: 10.1016/j.amjmed.2012.01.024_bib33
  article-title: Quality of life comparison between corticosteroid-and-mycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis
  publication-title: Lupus
  doi: 10.1191/0961203306lu2307xx
  contributor:
    fullname: Tse
– volume: 76
  start-page: 72
  year: 2009
  ident: 10.1016/j.amjmed.2012.01.024_bib28
  article-title: Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans
  publication-title: Kidney Int
  doi: 10.1038/ki.2009.66
  contributor:
    fullname: Suthanthiran
SSID ssj0000956
Score 2.1228445
SecondaryResourceType review_article
Snippet Abstract The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to...
The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 642
SubjectTerms Azathioprine
Biological and medical sciences
Cyclophosphamide
Cyclophosphamide - therapeutic use
General aspects
Humans
Immunosuppressive Agents - therapeutic use
Internal Medicine
Kidneys
Lupus
Lupus nephritis
Lupus Nephritis - drug therapy
Medical sciences
Medical treatment
Mycophenolate mofetil
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Nephrology. Urinary tract diseases
Quality of life
Risk factors
Urinary system involvement in other diseases. Miscellaneous
Title Recent Progress in the Treatment of Proliferative Lupus Nephritis
URI https://www.clinicalkey.es/playcontent/1-s2.0-S000293431200160X
https://dx.doi.org/10.1016/j.amjmed.2012.01.024
https://www.ncbi.nlm.nih.gov/pubmed/22608789
https://www.proquest.com/docview/1029922978/abstract/
https://search.proquest.com/docview/1022259102
Volume 125
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBahhTEYY_dl64oHeysOsiJb1ssgjJayJt1YHJY3IdkSNGNOtsQv-_U7suRL2nW3F2N8kWV9n47Okc45QugNLlRUYMNCqRgPKRvTkDNThLGMcsxJQWgdCzO7TM4X9P0yXg4Gb3teS9VOjfIfv4wr-R9U4RrgaqNk_wHZtlC4AOeALxwBYTj-Fcag89ml_I_Wx8pKLO-zmLXO49bBzW7LY7RP8D2tNpWVbAChTWbUV02zLsak7CeUuL76buMRapTll5OZXPenDaLOxdTPZTXxLHP9rVpfyZP5aHJNTvKxS6A00l40xnFo803tyU4XtexJwnqSMHFJs25IaDdZsBrJryuov_WtIy5vKu1GpGYV_vKDOFtMpyI7XWb7d-sBmDBCmM3HD9bvIWE8BuP7cHLx6fNFNxbzev_e9n-a4Mnaw-9mFW5TTu5t5Ba6jHF7ndxujNRKSfYA3ffWRDBx1HiIBrp8hO7MPGKP0cQxJGgYElyVATAkaBkSrE2wx5CgZkjQMuQJWpydZu_OQ79pRphTFu9CiQ0oxcxEjOVRimUag_qBFcMmKQqqNYf-o-OEU2rAch3LnOk0jQ3JacRTkxfjp-igXJf6OQoMN6oopIq0TqmkRqmcS065SgulcIyHKGxaS2xcbhTROA2uhGtdYVtX4EhA6w4Ra5pUNHG_MFLpref0VkRiCw-LucXLwhWReh_0Zf9Nrxk6jU8Arf7wzeM97NqKkgQskYiNh-ioAVN09YDPc0I4S4fodXsbBK9dTZOlXlf1MzAWgrZNhuiZI0FXOElwylL-4veFv0R3u655hA523yv9CnTcnTr2RP4JOvyl7Q
link.rule.ids 315,786,790,27957,27958
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+Progress+in+the+Treatment+of+Proliferative+Lupus+Nephritis&rft.jtitle=The+American+journal+of+medicine&rft.au=Chan%2C+Tak+Mao&rft.date=2012-07-01&rft.pub=Elsevier+Sequoia+S.A&rft.issn=0002-9343&rft.eissn=1555-7162&rft.volume=125&rft.issue=7&rft.spage=642&rft_id=info:doi/10.1016%2Fj.amjmed.2012.01.024&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=2722775781
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029343%2FS0002934311X00219%2Fcov150h.gif